An Open Label, Brain Positron Emission Tomography, Phase 0 Study of [18F]MNI-968 as a Marker for D1 Receptor in Healthy Subjects
Phase of Trial: Phase 0
Latest Information Update: 09 Mar 2018
Price : $35 *
At a glance
- Drugs 18F-MNI-968 (Primary)
- Indications Neurodegenerative disorders
- Focus Diagnostic use
- 05 Mar 2018 Status changed from recruiting to completed.
- 27 Apr 2017 Planned number of patients changed from 5 to 7.
- 24 Mar 2017 New trial record